Expert Review of Anticancer Therapy 2015
When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs.
只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
关键词
抽象
Crizotinib is an orally active multi-target tyrosine kinase inhibitor which is the standard of care in patients with anaplastic lymphoma kinase translocated non-small-cell lung cancer. Common adverse events in clinical trials with crizotinib included visual disorders, nausea-vomiting, diarrhea and elevated transaminases. Less common toxicities are emerging, such as bradycardia and QT interval prolongation. We report on a case of a presyncopal episode which occurred under crizotinib and metoclopramide treatment.